Erratum: Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome (Genetics in Medicine (2013) 13:2 (95-101) DOI: 10.1097/GIM.0b013e3181fea459);Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome

Genetics in Medicine

Volumn 13, Issue 2, 2011, Pages 95-101

  Muenzer, Joseph ^a   Beck, Michael ^b   Eng, Christine M ^c   Giugliani, Roberto ^d   Harmatz, Paul ^e   Martin, Rick ^f   Ramaswami, Uma ^g   Vellodi, Ashok ^h   Wraith, James E ⁱ   Cleary, Maureen ^h   Gucsavas Calikoglu, Muge ^a   Puga, Ana Cristina ^j   Shinawi, Marwan ^c   Ulbrich, Birgit ^g   Vijayaraghavan, Suresh ^k   Wendt, Susanne ^b   Conway, Anne Marie ^f   Rossi, Alexandra ^f   Whiteman, David A H ^f   Kimura, Alan ^l  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e CHILDREN S HOSPITAL OAKLAND   (United States)

^f SHIRE   (United States)

^g CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^h GREAT ORMOND STREET HOSPITAL   (United Kingdom)

ⁱ ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^j Genzyme Europe BV   (Netherlands)

^k BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^l Clinical Development   (United States)

more..

Author keywords

clinical trial; enzyme replacement therapy; Hunter syndrome; idursulfase; lysosomal storage disease; mucopolysaccharidosis type II

Indexed keywords

IDURONATE 2 SULFATASE; IMMUNOGLOBULIN G ANTIBODY; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILD HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX SCORE; CLINICAL ASSESSMENT TOOL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; ENZYME REPLACEMENT; ERYTHEMA; EXERCISE TEST; FLUSHING; FORCED VITAL CAPACITY; HEPATOSPLENOMEGALY; HUMAN; HUNTER SYNDROME; JOINT STIFFNESS; LIVER WEIGHT; LUNG FUNCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RANGE OF MOTION; SCHOOL CHILD; SHOULDER; SIDE EFFECT; SPLEEN WEIGHT; URTICARIA; WALKING;

EID: 79951578486     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2013.132     Document Type: Erratum

References (21)

1. Bach G, Eisenberg F Jr, Cantz M, Neufeld EF. The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase. Proc Natl Acad Sci USA 1973;70:2134-2138.
2. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver C, Beaudet A, Sly W, Valle D, editors. The metabolic and molecular bases of inherited diseases. New York: McGraw-Hill, 2001:3421-3452.
3. Martin R, Beck M, Eng C, et al. Recognition and diagnosis of mucopolysac-charidosis II (Hunter syndrome). Pediatrics 2008;121:e377-e386. (Pubitemid 351198459)
4. Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006;8:465-473.
5. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. [Lung volumes and forced ventilatory flows. Work Group on Standardization of Respiratory Function Tests. European Community for Coal and Steel. Official position of the European Respiratory Society.] Rev Mal Respir 1994;11(suppl 3):5-40.
6. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5-40.
7. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-187. (Pubitemid 29036522)
8. Polgar G, Promadhat V. Pulmonary function testing in children: techniques and standards. Philadelphia: W.B. Saunders and Company, 1971.
9. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994;37: 1761-1769. (Pubitemid 24371878)
10. Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344:182-188. (Pubitemid 32064139)
11. Schlesinger AE, Edgar KA, Boxer LA. Volume of the spleen in children as measured on CT scans: normal standards as a function of body weight. AJR Am J Roentgenol 1993;160:1107-1109. (Pubitemid 23141260)
12. Flato B, Sorskaar D, Vinje O, et al. Measuring disability in early juvenile rheumatoid arthritis: evaluation of a Norwegian version of the childhood Health Assessment Questionnaire. J Rheumatol 1998;25:1851-1858. (Pubitemid 28439284)
13. Dempster H, Porepa M, Young N, Feldman BM. The clinical meaning of functional outcome scores in children with juvenile arthritis. Arthritis Rheum 2001;44:1768-1774. (Pubitemid 32758222)
14. Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2002;1-190.
15. Wraith JE, Beck M, Giugliani R, Clarke J, Martin R, Muenzer J. Initial report from the Hunter Outcome Survey (HOS). Genet Med 2008;10:508-516.
16. Wraith JE, Tylki-Szymanska A, Guffon N, et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr 2008;152:563-570.
17. Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008;167:267-277.
18. Harmatz P, Giugliani R, Schwartz IV, et al. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccha-ridosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab 2008;94:469-475.
19. Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalac-tosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006;148:533-539.
20. Harmatz P, Ketteridge D, Giugliani R, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 2005;115:e681-e689. (Pubitemid 43843141)
21. Ries M, Clarke JT, Whybra C, et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 2006;118:924-932. (Pubitemid 46091613)